Navigation Links
ChartTrends®: Multiple Sclerosis Report Reveals the Latest Approach to the Treatment and Management of MS
Date:11/2/2010

EXTON, Pa., Nov. 2, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. has released a syndicated report focused on the management and treatment of multiple sclerosis (MS) in the US. ChartTrends®: Multiple Sclerosis is an annual publication based on patient level data collected on 1,000 MS patients being treated with disease modifying agents (DMAs).

In addition to helping to define the DMA-treated MS patient (demographics, co-morbidities, concomitant medications, prevalence of symptoms and symptomatic treatment), the report provides insight into the factors that drive decisions to initiate treatment and factors that drive DMA brand selection for both first line and switch patients. Profiles for patients treated with each DMA brand (Avonex, Betaseron, Copaxone, Rebif and Tysabri) are provided. There are a number of differences between patients treated with the various DMAs including MRI status, functioning, disease progression, clinical response and likelihood of switching to a pipeline DMA in the future. The most likely patient types for newly approved Gilenya and late-stage DMAs in development (e.g. Movectro, alemtuzumab, daclizumab) are identified. A number of patient characteristics, including disease classification and current DMA brand, influence the likelihood of a potential switch to Gilenya.

Since initiating on their most current DMA, one-third of patients have experienced an exacerbation with the most common symptoms including muscle weakness and gait/coordination issues. While most exacerbations are treated with short steroid pulses, the use of chronic pharmacological treatment is common for management of spasticity, pain syndromes, bladder/bowel dysfunction, depression/apathy and fatigue. The patient types being selected for treatment with Ampyra, the first FDA-approved symptomatic agent for MS launched in March 2010, are identified in the report.

About BioTrends Research Group, Inc.BioTrends Research Group,
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. New Orthopedic Market Research Data Covering Multiple Geographies Released by Millennium Research Group
2. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
3. ARIKACE™ Demonstrates Sustained Benefit in Multiple Studies and Over Multiple Cycles of Treatment of Pseudomonas Lung Infections in Cystic Fibrosis Patients
4. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
5. Teriflunomide Successfully Reduces Relapses and is Well Tolerated in Multiple Sclerosis Patients
6. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Reportlinker Adds Multiple Sclerosis (MS) Drugs and Biologics: Technologies and Global Markets
9. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
10. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
11. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... , April 16, 2015  Hologic, Inc. (NASDAQ: ... cancer screening study i published on-line this ... journal of the American Cancer Society. ... the University of Pittsburgh Medical Center, supports current consensus guidelines ... that women 30-65 years of age be co-tested ...
(Date:4/16/2015)... April 16, 2015 Mallinckrodt plc (NYSE: ... today announced that it has completed its acquisition ... approximately $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s ... reach into neonatal critical care with INOMAX ® ... for a highly vulnerable patient population. It also ...
(Date:4/16/2015)... , April 16, 2015  Rosewind Corporation (OTCMKTS: ... reverse merger with a newly formed specialty healthcare ... focus on addressing urological disorders. The merged company, ... Inc., has commenced operations and incorporates the pipeline ... The Company,s strategy is to build a late-stage ...
Breaking Medicine Technology:Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 2Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 3Hologic Comments on Important Cervical Cancer Screening Study Published in the American Cancer Society Journal, Cancer Cytopathology 4Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 2Rosewind Corporation Shifts Focus to Develop Late-Stage Therapeutics for Urological and Related Conditions 3
... Fla., May 26, 2011 Tigris Pharmaceuticals, Inc., today ... Phase 2 clinical trial of AFP-464 (aminoflavone prodrug) with ... cancer patients. Molecular profiling will be used to pre-screen ... which has shown to predict sensitivity to ...
... 26, 2011 Medical Affairs serves as the linchpin for ... a successful market entry of a new product. ... trial strategy & planning, and publication strategy & planning, are ... the activities where organizations turn to Medical Affairs to play ...
Cached Medicine Technology:Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 2Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients 3Medical Affairs Role in New Product Planning Detailed in Best Practices, LLC Report 2
(Date:4/17/2015)... 17, 2015 In Defense of Christians ... statement: “On Wednesday April 15th, the European Parliament joined ... resolution recognizing the Armenian Genocide, “paying tribute, on the ... one-and-a-half million innocent Armenian victims who perished in the ... the EU for this timely and needed recognition of ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 At ... Entertainment’s EcoLuxe Lounge and the “Salute to the Oscars” ... luxurious Beverly Hilton Hotel, overlooking the impressive Los Angeles ... were organized by Debbie Durkin, LA’s leading producer of ... Showcasing many of the world’s premier providers of eco-friendly ...
(Date:4/17/2015)... Scientists from the Icahn School ... U.S. and Venezuelan researchers, have discovered the most ... an isolated tribe of Yanomami Amerindians in the ... the Yanomami, previously unexposed to antibiotics or industrialized ... of people living in industrialized countries, and was ...
(Date:4/17/2015)... North Carolina (PRWEB) April 17, 2015 ... Family Dental Care has spent the last four ... dental care, performing procedures ranging from general cleanings to ... host a grand opening at their new office in ... the same services as their Concord office, including denture ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Ticket Down is a ... their 2015 Summer Tour. , The life of last-minute show announcements ... the popular group perform during the early part of 2015, but ... Will Wait,” “Little Lion Man,” “The Cave,” and “Believe,” will perform ... on June 2 at MCU Park at Coney Island in Brooklyn, ...
Breaking Medicine News(10 mins):Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 2Health News:Mount Sinai Scientists Find Unprecedented Microbial Diversity in Isolated Amazonian Tribe Previously Unexposed to Antibiotics or Processed Foods 3Health News:Mumford and Sons Tickets in Clarkston/Detroit, Raleigh, Columbia/Baltimore, Chicago, Mansfield/Boston, Brooklyn, Calgary and Edmonton Now On Sale 2
... treatment has been found beneficial for boys affected by Duchenne muscular ... steroids helps them to walk on their own for a longer ... ,Duchenne muscular dystrophy occurs in one in 3,500 boys. Symptoms start ... ability to walk between ages nine and 11. There is no ...
... blessing for those women who are on estrogen therapy before the ... of reduction in the risk of Alzheimers disease or dementia. ... estrogen hormone therapy before the age of 65 cut their risk ... on hormone therapy before the age of 65. ...
... anymore for low test scores. According to American research, ... of their conception-which unfortunately they cant help. ... Paul Winchester of Indiana University School of Medicine claimed ... to perform worse than their peers in examinations. ...
... A widely used diabetes drug dramatically boosted the potency of ... cancer cell lines and to mice with tumors, scientists ... chemotherapy agent and the diabetes drug rosiglitazone halted or shrank ... either of the drugs given alone, according to the article ...
... a common condition among the senior lot in Australia. This is ... from an illness or accident. ,A study of ... almost 80 per cent were malnourished. At the same time, the ... were able to reduce their period of stay in the hospital. ...
... so that almost one in five babies rooms sport a television ... babies are sworn friends with the television by the age of ... to a survey by University of Texas researchers, 63 percent of ... switch it on or off at will. On an average babies ...
Cached Medicine News:Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2Health News:Low Test Scores Of Children Linked To Their Date Of Conception 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 2Health News:Diabetes Drug Dramatically Boosts Potency of Platinum Chemotherapy 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: